Skip to main content

Table 1 Description of cases screened for BRCA1 and BRCA2 mutations

From: A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population

Group (Period of ascertainment, years) Histological subtype 1 Number of women with ovarian cancer (fallopian tube 2 and primary peritoneal cancers) Tumour grade Disease stage 3 Mean age of diagnosis (range), years
G1 G2 G3 Un-classified I II III IV
All (1997–2011) Serous 369 (9) 12 62 279 16 25 28 275 40 61 (24 – 91)
Endometrioid 30 (0) 0 20 9 1 13 2 14 1 58 (41 – 82)
Mixed cell 32 (0) 0 11 21 0 6 2 21 3 57 (36 – 77)
Undifferentiated 8 (1) 12 0 3 4 2 0 6 0 61 (33 – 72)
All types 439 (10) 13 93 312 21 46 32 316 44 61 (24 – 91)
Subgroup (2006–2008) Serous 92 (4) 3 11 73 5 7 8 68 9 61 (38 – 82)
Endometrioid 9 (0) 0 7 2 0 6 1 2 0 58 (41 – 82)
Mixed cell 12 (0) 0 2 10 0 3 1 6 2 60 (40 – 77)
Undifferentiated 3 (1) 12 0 1 1 1 0 2 0 68 (62 – 71)
All types 116 (5) 4 20 86 6 17 10 78 11 61 (38 – 82)
  1. 1Mixed cell has components of serous subtype cancer cells; 2fallopian tube adenocarcinoma; 3staging information was not available for a women with a serous ovarian carcinoma diagnosed at 91 years of age.